ArticlePDF Available

Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats

Authors:

Abstract and Figures

Using the place-preference conditioning paradigm, we evaluated the potential of the two most prominent cannabinoids found in marijuana, the psychoactive component delta9-tetrahydrocannabinol (delta9-THC) and the nonpsychoactive component cannabidiol (CBD), to potentiate extinction of a cocaine-induced and an amphetamine-induced conditioned place preference in rats. To determine the effects of pretreatment with delta9-THC or CBD on extinction, a cocaine-induced and amphetamine-induced place preference was first established. Rats were then given an extinction trial, during which they were confined to the treatment-paired floor for 15 min. Thirty minutes prior to the extinction trial, they were injected with a low dose of delta9-THC (0.5 mg/kg), CBD (5 mg/kg) or vehicle. The potential of the CB1 receptor antagonist, SR141716, to reverse the effects of delta9-THC or CBD was also evaluated. To determine the hedonic effects of CBD, one distinctive floor was paired with CBD (5 mg/kg) and another with saline. Finally, to determine the effect of delta9-THC.or CBD on the establishment and/or the expression of a place preference during four cycles of conditioning trials, rats were injected with delta9-THC (0.25-1 mg/kg), CBD (5 mg/kg) or vehicle 25 min prior to receiving an injection of amphetamine followed by placement on the treatment floor; on alternate days, they received injections of vehicle followed by saline and placement on the nontreatment floor. The rats then received two test trials; on one trial they were pretreated with the cannabinoid and on the other trial with vehicle. delta9-THC and CBD potentiated the extinction of both cocaine-induced and amphetamine-induced conditioned place preference learning, and this effect was not reversed by SR141716. The cannabinoids did not affect learning or retrieval, and CBD was not hedonic on its own. These results are the first to show that both delta9-THC, which acts on both CB 1 and CB2 receptors, and CBD, which does not bind to CB1 or CB2 receptors, potentiate the extinction of conditioned incentive learning.
Content may be subject to copyright.
Psychopharmacology (2004) 175:360–366
DOI 10.1007/s00213-004-1825-7
ORIGINAL INVESTIGATION
Linda A. Parker · Page Burton · Robert E. Sorge ·
Christine Yakiwchuk · Raphael Mechoulam
Effect of low doses of D
9
-tetrahydrocannabinol and cannabidiol
on the extinction of cocaine-induced and amphetamine-induced
conditioned place preference learning in rats
Received: 21 October 2003 / Accepted: 25 January 2004 / Published online: 5 May 2004
Springer-Verlag 2004
Abstract Rationale: Using the place-preference condi-
tioning paradigm, we evaluated the potential of the two
most prominent cannabinoids found in marijuana, the
psychoactive component D
9
-tetrahydrocannabinol (D
9
-
THC) and the nonpsychoactive component cannabidiol
(CBD), to potentiate extinction of a cocaine-induced and
an amphetamine-induced conditioned place preference in
rats. Methods: To determine the effects of pretreatment
with D
9
-THC or CBD on extinction, a cocaine-induced
and amphetamine-induced place preference was first es-
tablished. Rats were then given an extinction trial, during
which they were confined to the treatment-paired floor for
15 min. Thirty minutes prior to the extinction trial, they
were injected with a low dose of D
9
-THC (0.5 mg/kg),
CBD (5 mg/kg) or vehicle. The potential of the CB
1
re-
ceptor antagonist, SR141716, to reverse the effects of D
9
-
THC or CBD was also evaluated. To determine the he-
donic effects of CBD, one distinctive floor was paired
with CBD (5 mg/kg) and another with saline. Finally, to
determine the effect of D
9
-THC or CBD on the estab-
lishment and/or the expression of a place preference
during four cycles of conditioning trials, rats were in-
jected with D
9
-THC (0.25–1 mg/kg), CBD (5 mg/kg) or
vehicle 25 min prior to receiving an injection of am-
phetamine followed by placement on the treatment floor;
on alternate days, they received injections of vehicle
followed by saline and placement on the nontreatment
floor. The rats then received two test trials; on one trial
they were pretreated with the cannabinoid and on the
other trial with vehicle. Results: D
9
-THC and CBD po-
tentiated the extinction of both cocaine-induced and am-
phetamine-induced conditioned place preference learning,
and this effect was not reversed by SR141716. The
cannabinoids did not affect learning or retrieval, and CBD
was not hedonic on its own. Conclusions: These results
are the first to show that both D
9
-THC, which acts on both
CB1 and CB2 receptors, and CBD, which does not bind to
CB
1
or CB
2
receptors, potentiate the extinction of con-
ditioned incentive learning.
Keywords Memory · Cannabinoids ·
D
9
-Tetrahydrocannabinol · Cannabidiol · Extinction ·
Cocaine · Amphetamine · Conditioned place-preference
learning · Incentive · Classical conditioning
For organisms to gain maximum benefit from their en-
vironment, they must not only learn new associations, but
also extinguish associations that are no longer useful.
Recent evidence implicates the endogenous cannabinoid
system in the extinction process (Marsicano et al. 2002;
Varvel and Lichtman 2002). Marsicano et al. (2002) re-
ported that CB
1
knockout mice show impaired extinction,
in auditory fear-conditioning tests, with unaffected
memory acquisition and consolidation. Furthermore,
treatment of wild-type mice with the CB
1
antagonist,
SR141716 (SR), mimicked the response of CB
1
deficient
mice, suggesting that activation of the CB
1
receptor is
involved in extinction of learned memories. Using a very
different task, the Morris water maze, Varvel and Licht-
man (2002) reported that CB
1
knockout mice and wild-
type mice exhibit identical acquisition rates in learning to
swim to a fixed platform; however, the CB
1
-deficient
mice demonstrate considerable deficits in a reversal task
in which the location of the hidden platform is moved to
the opposite side of the tank. The difference in perfor-
mance was attributed to disruption of extinction of the
L. A. Parker (
)
) · P. Burton · C. Yakiwchuk
Department of Psychology,
Wilfrid Laurier University,
Waterloo, ON, Canada, N2L 3C5
e-mail: lparker@wlu.ca
Tel.: +1-519-884-0710
Fax: +1-519-746-7605
R. E. Sorge
Center for Studies in Behavioural Neuroscience,
Concordia University,
Montreal, QC, Canada
R. Mechoulam
Department of Medicinal Chemistry and Natural Products,
Hebrew University of Jerusalem,
Jerusalem, Israel
learned response. These results suggest that the endoge-
nous cannabinoid system modulates extinction of learned
responses.
Since animals deficient in CB
1
receptors show a failure
to extinguish learned behavior, cannabinoid agonists
might be expected to facilitate extinction of learned be-
haviors in nondeficient animals. The most prevalent
cannabinoids found in marijuana are the psychoactive
component D
9
-tetrahydrocannabinol (D
9
-THC) and the
nonpsychoactive component (Mechoulam et al. 2002)
cannabidiol (CBD). Unlike D
9
-THC, CBD does not bind
to CB
1
or CB
2
receptors; instead it may act by blocking
the reuptake of anandamide or act on an unknown re-
ceptor (Mechoulam et al. 2002). In mice and rats re-
spectively, CBD is a highly effective anti-inflammatory
agent (Malfait et al. 2000) and plays a role in the sup-
pression of nausea (Parker et al. 2002). The experiments
described here evaluated the potential of low doses of D
9
-
THC and CBD to modulate extinction of cocaine and
amphetamine incentive learning using the place-prefer-
ence procedure. Conditioned incentive learning has been
suggested to play a role in craving (Robinson and Ber-
ridge 1993; DeWit and Stewart 1981); therefore, treat-
ments that potentiate extinction of conditioned incentive
learning may be useful in the control of craving.
Place-preference learning is a commonly used measure
of positive incentive learning (Cunningham 1998). In the
typical procedure, a drug is paired with one distinctive
environment and vehicle is paired with another. Follow-
ing conditioning, the animal is given access to both
contexts in a drug-free state. A conditioned place pref-
erence is demonstrated if the animal spends a greater
amount of time in the drug-paired environment than the
vehicle-paired environment. The preference demonstrates
that the conditioned stimulus (CS) environment associ-
ated with the drug effects has acquired conditioned in-
centive properties (Robinson and Berridge 1993; Cun-
ningham 1998). Place-preference learning follows the
principles of classical conditioning, including extinction.
In extinction, animals display a reduced approach to the
CS context following its experience in the absence of the
unconditioned stimulus (UCS) drug (Bardo et al. 1986;
Calcagnetti and Schechter 1993; Tzschentke and Schmidt
1995; Cunningham et al. 1998; Parker and McDonald
2000; Meuller et al. 2000; Itzhak and Martin 2002).
There are two sets of experiments reported here. The
first set evaluated the effects of nonhedonic doses of D
9
-
THC and CBD to promote extinction of place-preference
learning and the potential of SR to reverse this effect. The
second set evaluated the effect of D
9
-THC and CBD on
the acquisition and/or initial expression of place-prefer-
ence learning. The doses of D
9
-THC were selected on the
basis of prior work indicating that they are neither re-
warding nor aversive (Parker and Gillies 1995; Mallet and
Beninger 1998b; Robinson et al. 2003), yet they have a
physiological effect of suppression of nausea (Limebeer
and Parker 1999; Parker et al. 2003). The dose of CBD
(5 mg/kg) was selected on the basis of prior work that has
shown it to be effective in suppressing nausea in rats
(Parker et al. 2003), inflammatory pain in mice (Malfait et
al. 2000), and vomiting in shrews (Parker et al. 2004;
Kwiatkowska et al. 2004). Additionally, the potential of
CBD to produce place conditioning on its own was
evaluated.
Materials and methods
Subjects
The subjects were experimentally naive male Sprague-Dawley rats
weighing between 250 g and 310 g on the first conditioning day.
They were pair-housed in Plexiglas cages (472620 cm) with
unrestricted access to food and water, except as specified. The room
was illuminated on a 12-h/12-h light/dark schedule with the lights
on at 0800 hours, and all procedures occurred in the light. Upon
arrival in the laboratory, the rats were handled daily for 1 week
prior to the conditioning trials. All procedures were approved by
the Institutional Animal Care Committee according to the guide-
lines of the Canadian Council for Animal Care.
Drugs
All drugs were injected intraperitoneally (i.p.). D
9
-THC [supplied
by the National Institute on Drug Abuse (NIDA)], CBD (supplied
by R. Mechoulam) and SR (supplied by NIDA) were prepared in a
solution of 1 ml ethanol/1 ml Cremaphor (Sigma)/18 ml saline. D
9
-
THC was prepared as a 0.5-mg/ml solution of the vehicle and was
administered at a volume of 0.5, 1.0 or 2.0 ml/kg (0.25, 0.5, 1.0 mg/
kg), depending on the experiment. CBD was prepared as a 5-mg/ml
solution of the vehicle and was administered in a volume of 1 ml/kg
(5 mg/kg). SR was prepared as a 2.5-mg/ml solution of vehicle and
was administered at a volume of 1 ml/kg (2.5 mg/kg). Vehicle was
administered in a volume of 1 ml/kg. Cocaine HCl (supplied by
NIDA) was prepared in a solution of 5 mg/ml (expressed as the salt)
and administered in a volume of 3 ml/kg (15 mg/kg). Amphetamine
(supplied by NIDA) was prepared in a solution of 1 mg/ml and
injected in a volume of 3 ml/kg (3 mg/kg).
Apparatus
The place-preference apparatus consisted of a black Plexiglas
rectangular box (602525 cm) with a mesh top. The black
Plexiglas floors of the box were interchangeable. During condi-
tioning, the entire floor of the apparatus consisted of either small
holes (1 cm in diameter arranged 1 cm apart from one another) or
wire mesh (1-cm squares) attached to the black Plexiglas floor. For
half of the rats, the hole floor was the treatment floor and for the
other half of the rats the mesh floor was the treatment floor.
During testing, three floors were inserted into the apparatus: one
made of holes (25 cm25 cm), one made of mesh (25 cm25 cm)
and a center floor made of smooth black Plexiglas (9 cm25 cm).
The tactile stimulus properties of the hole and the mesh floors were
the same as those used in conditioning. The novel smooth black
Plexiglas floor was placed in the center of the chamber and the hole
and mesh floors were placed on either side (with the side coun-
terbalanced among the groups). The amount of time that each rat
spent on each of the three floors was automatically recorded using a
camera mounted to the ceiling that sent the signal to a computer.
The signal was recorded and subsequently analyzed by the Noldus
Etho-Vision videotracking system (Noldus Information Technolo-
gy, Sterling, VA).
Prior to the experiments described below, the rats were given a
single 15-min pretest in the testing apparatus. In none of these tests
was there a significant difference between the time spent on the
mesh floor and on the holes floor indicating that the apparatus
provides an unbiased test of place conditioning (e.g., Cocaine US:
361
mesh, mean=430 s, SEM=12.4; holes, mean=416 s, SEM=12.4;
t
47
=0.9).
Procedure
Experiment 1: effect of nonhedonic doses of CBD
and THC on extinction of place-preference learning
Experiment 1a: evaluation of the potential of CBD to produce place
conditioning. On each of four conditioning trial cycles, rats in
group CBD (n=12) were injected with 5 mg/kg CBD or vehicle
(1 ml/kg), 5 min prior to placement in a chamber with a distinctive
floor (holes or mesh) for 30 min. A conditioning cycle consisted of
one CBD trial and one vehicle trial separated by 24 h. The floors
were removed and washed following each trial. The order of the
CBD trial within a cycle and the floor paired with CBD were
counterbalanced. Rats in group VEH (n=12) were injected with
vehicle on each trial; the floor designated as the treatment-paired
floor was randomly determined. Each of the cycles of conditioning
was separated by 48–72 h. Seventy-two hours after the final con-
ditioning trial, the rats all received a 15-min place-preference test in
the test apparatus, and the amount of time spent on each floor was
monitored.
Experiment 1b: effect of THC and CBD on extinction
of cocaine-induced and amphetamine-induced place preference.
Pretest
All rats received a 15-min drug-free pretest in the testing ap-
paratus to determine baseline preference for the floors. The activity
of the rat was automatically recorded. Following each pretest,
conditioning trial and test trial, the floors were removed and wa-
shed.
Conditioning
For cocaine, rats were given two (n=36) or four (n=48) condi-
tioning cycles, during which they were injected with cocaine or
saline 5 min prior to placement in a chamber with a distinctive floor
(holes or mesh) for 30 min. A conditioning cycle consisted of one
cocaine trial and one saline trial separated by 24 h. The order of the
cocaine trial within a cycle and the floor paired with cocaine were
counterbalanced. Each of the cycles of conditioning was separated
by 48–72 h. For amphetamine, the rats were given four condi-
tioning cycles (n=36), during which they were injected with am-
phetamine or saline 5 min prior to placement in the conditioning
apparatus, as described above. For saline, an additional 24 rats were
given four conditioning cycles, as described above, except that they
received saline injections 5 min prior to placement in each of the
floors. One floor was designated as the treatment-paired floor and
the other was designated as the nontreatment-paired floor by ran-
dom assignment.
Extinction
Seventy-two hours after the final conditioning trial, the rats
(n=8–12 per group) were injected with 0.5 mg/kg D
9
-THC, 5 mg/kg
CBD or vehicle (1 ml/kg), 30 min prior to receiving a single ex-
tinction trial during which they were confined to the treatment-
paired floor for 15 min. Among the cocaine and amphetamine
conditioned groups, an additional group of rats (no extinction; n=8–
12 per group) were not given the extinction trial; they remained in
their home cage on the day of extinction.
Testing
All rats received a place-preference test 48 h following the
extinction trial. They were placed in the test apparatus for 15 min,
and the amount of time spent on each floor was automatically
recorded.
Experiment 1c: effect of SR on D9-THC and CBD modulation of
extinction. The potential of the CB
1
receptor antagonist, SR to
reverse modulation of extinction by D
9
-THC (0.5 mg/kg) and CBD
(5 mg/kg) was evaluated in two replications that produced a similar
pattern of results and were, therefore, pooled. The dose of 2.5 mg/
kg i.p. was selected on the basis of findings that this dose, but not
1 mg/kg, reversed the effects of the synthetic cannabinoid, HU-210,
on lithium-induced conditioned gaping in rats (Parker et al. 2003).
The rats received a total of four cycles of conditioning with am-
phetamine using an identical conditioning and testing procedure as
described above. Seventy-two hours after the final conditioning
trial, the rats received a single 15-min extinction trial that began
30 min after they were injected i.p. (with 5 min between injections)
with two solutions: SR-D
9
-THC (n=21), SR-CBD (n=21), SR-VEH
(n=21), VEH–VEH (n=21).
Experiment 2: evaluation of effect of D
9
-THC and CBD
on the establishment and the expression
of amphetamine-induced place-preference learning
D9-THC. On each of four conditioning cycles (separated by 48–
72 h), 48 rats received a 30-min treatment trial following an in-
jection of 3 mg/kg amphetamine and a 30-min nontreatment trial
following an injection of saline. The treatment and nontreatment
trials were separated by 24 h. On the treatment trial, various groups
(n=12 per group) were injected with vehicle, 0.25 mg/kg, 0.5 mg/kg
or 1.0 mg/kg D
9
-THC, 30 min prior to the injection of amphet-
amine. On the nontreatment trial, all rats were injected with vehi-
cle, 30 min prior to the injection of saline. The floor paired with the
treatment and the order of the trials was counterbalanced. In order
to evaluate the effect of D
9
-THC on the expression of a previously
established place preference, the rats received two test trials, the
vehicle test trial occurred 30 min following an injection of vehicle
and the D
9
-THC test trial occurred 30 min following an injection of
D
9
-THC. The dose of D
9
-THC administered on the D
9
-THC test
trial was the same dose given during conditioning; group VEH
received a dose of 0.5 mg/kg D
9
-THC on the test trial. The order of
D
9
-THC and VEH test trials were counterbalanced.
Cannabidiol. The effect of CBD on the establishment and the ex-
pression of amphetamine place-preference learning was evaluated.
During each of four conditioning cycles, on the treatment trial, the
rats received an injection of 5 mg/kg CBD (n=9) or vehicle (n=9)
30 min prior to an injection of amphetamine 5 min prior to
placement on one floor for 30 min. On the nontreatment trial, they
received an injection of vehicle 30 min prior to an injection of
saline 5 min prior to placement on the other floor for 30 min. The
order of trials within a cycle and the floor paired with amphetamine
were counterbalanced. The test trials began 72 h later. On one test
trial, rats were pretreated with 5 mg/kg CBD and, on the other test
trial, they were pretreated with vehicle (5 ml/kg) 30 min prior to a
15-min place-preference test. The trials were separated by 24 h, and
the order was counterbalanced across the groups.
Data analysis
The data were converted to difference scores in the following
manner: mean seconds on the treatment-paired floor minus the
nontreatment-paired floor. Therefore, a value of 0.0 represents
neither a preference nor aversion to the floor. Groups were com-
pared using factorial analyses of variance (ANOVAs) with pairwise
least significant difference (LSD) tests when appropriate. Addi-
tionally, single sample t-tests compared the mean difference score
of each group with a value of 0.0.
Results
Experiment 1a: CBD and place conditioning
CBD produced neither a place preference nor aversion.
During the test trial, the mean seconds spent on the
362
treatment-paired floor minus the nontreatment-paired
floor by group CBD (mean=120 s, SEM=84.0) did not
significantly differ from that of group VEH (mean=53 s,
SEM=61.1). Neither of these scores differed significantly
from a value of 0.0 assessed by single sample t-tests.
Experiment 1b: effect of D
9
-THC and CBD
on extinction of cocaine-induced
and amphetamine-induced place preference
Cocaine
When administered during extinction training, both D
9
-
THC and CBD potentiated extinction of cocaine-induced
place-preference learning, regardless of the number of
conditioning trials. The mean (€SEM) number of seconds
that the rats in each group spent on the cocaine-paired
minus the saline-paired floor is presented in Fig. 1. A 42
ANOVA, with the between group factors of groups (no
extinction, VEH, CBD and D
9
-THC) and number of
conditioning trials (2 or 4), revealed only a significant
main effect of groups (F
3, 76
=4.6; P<0.01). Both groups
given the cannabinoid (D
9
-THC or CBD) during extinc-
tion spent less time on the cocaine-paired floor than either
the group given the vehicle during extinction (P val-
ues<0.05) or than the group given no extinction trial (P
values<0.05). Single-sample t-tests, pooled across the
factor of number of conditioning trials, revealed that
groups no extinction (t
19
=4.0; P<0.001) and vehicle
[t
(21)3.9
; P<0.001] displayed a place preference defined as
a significant difference from 0.0; however groups D
9
-
THC and CBD displayed neither a place preference nor a
place aversion.
Amphetamine
When administered during extinction training, D
9
-THC
and CBD both potentiated the extinction of an amphet-
amine-induced place preference. Figure 2 presents the
mean (€SEM) seconds on the amphetamine-paired floor
minus the saline-paired floor for the groups pretreated
with VEH, CBD, D
9
-THC and those that received no
extinction. A single-factor ANOVA indicated that the
groups significantly differed (F
3, 32
=4.7; P<0.01). Subse-
quent LSD comparison tests revealed that those rats re-
ceiving either no extinction or vehicle displayed a greater
preference for the amphetamine-paired floor than those
rats pretreated with CBD or D
9
-THC prior to a single
extinction trial (P values<0.05). Single-sample t-tests re-
vealed that groups VEH (t
8
=3.0; P<0.025) and no ex-
tinction [t
(8)4.4
; P<0.01] displayed a difference score
greater than 0.0, but groups CBD and D
9
-THC did not
differ significantly from a value of 0.0.
Saline
When administered during extinction training, neither
CBD nor D
9
-THC changed baseline floor preference; the
effect of extinction condition was not significant.
Fig. 1 Mean (€SEM) seconds on the cocaine-paired floor minus
the saline-paired floor by the various extinction groups previously
given two or four conditioning trial cycles. Asterisks (*P<0.05;
**P<0.01) indicate means that differed significantly from a value
of 0.0
Fig. 2 Mean (€SEM) seconds on the amphetamine-paired floor
minus the saline-paired floor by the various extinction groups.
Asterisks (*P<0.05; **P<0.01) indicate means that differed sig-
nificantly from a value of 0.0
363
Experiment 1c: effect of SR on D
9
-THC
and CBD modulation of extinction
As is apparent in Fig. 3, SR did not reverse the potentiated
extinction produced by either D
9
-THC or CBD. A single-
factor ANOVA revealed a significant extinction drug
effect (F
3, 80
=3.4; P=0.021). Subsequent pairwise com-
parison tests revealed that group VEH–VEH displayed a
significantly greater place preference than groups SR-D
9
-
THC or SR-CBD (P values<0.05), but did not differ from
group SR–VEH. However, group SR–VEH did not sig-
nificantly differ from groups SR-D
9
-THC or SR-CBD.
Single sample t-tests indicated that groups VEH–VEH
(P<0.001) and SR–VEH (P<0.05), but not groups SR–D
9
-
THC or SR–CBD, differed significantly from a value of
0.0.
Experiment 2. Effect of D
9
-THC or CBD
on the establishment and expression
of amphetamine place-preference conditioning
Neither D
9
-THC nor CBD affected either the establish-
ment or the expression of amphetamine-induced place-
preference learning. For D
9
-THC, the 42 mixed-factors
ANOVA with the between-groups factor of conditioning
pretreatment (0, 0.25, 0.5 or 1.0 mg/kg D
9
-THC) and the
within-groups factor of test pretreatment (VEH or D
9
-
THC) revealed no significant effects; however, a single
sample t-test for each test trial pooled across groups re-
vealed that rats displayed a place preference (as defined
as a difference from 0.0) on both the VEH test trial
[t
47
=7.0; P<0.001] and on the D
9
-THC test trial [t 47=7.5;
P<0.001].
For CBD, a 22 mixed-factors ANOVA with the be-
tween-groups factor of conditioning pretreatment (CBD
or VEH) and within-groups factor of test pretreatment
(CBD or VEH) revealed no significant effects; but a
single sample t-test pooled across conditioning pretreat-
ment groups revealed that rats displayed a place prefer-
ence (differed from 0.0) on both the VEH test trial
(t
17
=2.80; P<0.025) and the CBD test trial (t
17
=3.06;
P<0.01).
General discussion
Low doses of the principal cannabinoids found in mari-
juana—the psychoactive component D
9
-THC and the
nonpsychoactive component CBD—both potentiated the
extinction of cocaine place-preference and amphetamine
place-preference learning. This effect was not simply a
summation of the hedonic properties of the cannabinoids
and the incentive properties of the stimulant-paired place,
because rats conditioned with saline on both trials of each
cycle and extinguished with the cannabinoids did not
avoid the floor paired with the cannabinoid during the
extinction trial. Furthermore, when administered over
four conditioning cycles, the dose of CBD that potentiated
extinction of cocaine-induced and amphetamine-induced
place-preference learning produced neither a place aver-
sion nor a place preference. However, given that the
variability was high in the CBD conditioned groups, it is
possible that further training would have produced a place
aversion. Previous work indicated that, at the low doses
employed in these experiments, D
9
-THC produces neither
a place preference nor place aversion (Parker and Gillies
1995; Mallet and Beninger 1998b, Robinson et al. 2003).
Therefore, as has been shown with fear conditioning
(Marsicano et al. 2002) and spatial learning (Varvel and
Lichtman 2002), the cannabinoid system appears to play a
role in the extinction of conditioned incentive learning.
Two findings from this first set of experiments suggest
that the cannabinoid potentiation of extinction is not
mediated by action on known cannabinoid receptors: (1)
not only D
9
-THC, but also CBD which does not bind to
the CB
1
or CB
2
receptor (Mechoulam et al. 2002), pro-
moted extinction, and (2) the CB1 receptor antagonist, SR
(2.5 mg/kg), did not reverse the potentiation of extinction
by D
9
-THC. These results suggest that the effect of these
agents on extinction of positive incentive learning may
not be CB
1
mediated. Indeed, there is recent evidence that
the synthetic cannabinoid agonist WIN55,212-2 inhibits
glutamatergic transmission in CB1 (/) mice, indicating
that a novel cannabinoid-sensitive receptor may be re-
sponsible for this inhibition (Hajos et al. 2001).
Although a dose of 2.5 mg/kg SR is well above the
threshold to reverse the effect of CB1 agonists, it is
possible that a higher dose may have been more effective.
It is also possible that SR may have produced effects on
its own in this paradigm. Rats pretreated with SR-VEH
did not differ from those pretreated with SR-THC or SR-
CBD during extinction training. Therefore, it is conceiv-
able that SR may have produced a motivational effect
during extinction training. It has been shown that when
administered on multiple conditioning trials, SR produces
a place preference at doses ranging from 0.25 mg/kg to
3.0 mg/kg (Cheer et al. 2000); therefore, it is possible that
the exposure to the antagonist during extinction training
Fig. 3 Mean (+SEM) seconds on the amphetamine-paired floor
minus the saline-paired floor among the groups that varied by ex-
tinction experience. Asterisks (*P<0.05; **P<0.01) indicate means
that differed significantly from a value of 0.0
364
could have resulted in apparent reversal of the effects of
CBD or D
9
-THC on extinction because of the re-estab-
lishment of a preference.
Although the cannabinoids potentiated extinction,
neither D
9
-THC nor CBD affected the establishment or
the expression of amphetamine place preference. This is
consistent with reports that CB
1
knockout mice were
unimpaired in the acquisition or the initial expression of
conditioned fear (Marsicano et al. 2002) or spatial
learning in the Morris water maze (Varvel and Lichtman
2002). The finding that cannabinoids have a different
effect on acquisition and extinction suggests that these
processes are mediated by different mechanisms. Indeed,
recent evidence indicates that the cellular changes that
occur in extinction of cocaine self-administration differ
from those during acquisition or consolidation (Sutton et
al. 2003).
Although considerable evidence suggests that D
9
-THC
interferes with working memory (Lichtman and Martin
1996; Molina-Holgado et al. 1995; Nakamura et al. 1991;
Mallet and Beninger 1998a; Heyser et al. 1993; Varvel et
al. 2001) and to a lesser extent with reference memory
(Brodkin and Moerschbaecher 1997; Nava et al. 2000;
Varvel et al. 2001), the doses (1.5–18 mg/kg) employed in
such studies are considerably higher than the dose em-
ployed in the present experiments (0.5 mg/kg). In fact, at
the doses that interfere with learning and memory, D
9
-
THC also produces a conditioned place aversion (Parker
and Gillies 1995; Mallet and Beninger 1998b; Robinson
et al. 2003), suggesting that nonspecific aversive prop-
erties of D
9
-THC may interfere with performance.
Recent evidence suggests that cannabinoids may pro-
mote relapse to drug self-administration. DeVries et al.
(2001) demonstrated that the potent cannabinoid agonist
HU-210 reinstates cocaine self-administration on its own,
although Schenk and Partridge (1999) reported that THC
does not promote cocaine self-administration. Since the
phenomenon of reinstatement may be related to relapse to
the previously reinforced behavior, one might expect that
a treatment that potentiates extinction should attenuate
rather than promote reinstatement. However, different
processes are called upon during extinction training than
during priming. During extinction, the rat is exposed to
the CS in the absence of the US and thus learns a CS–no
US new association; it has been argued that the endoge-
nous cannabinoid system plays a role in this type of
learning (Marsicano et al. 2002). However, during prim-
ing, re-exposure to the US is argued to retrieve the in-
centive value of the previously extinguished CS (DeWit
and Stewart 1981). It is therefore, possible that the en-
dogenous cannabinoid system plays a different role in
extinction and in priming. Additionally, the dose of HU-
210 (0.02 mg/kg) required to promote relapse to cocaine-
seeking behavior (DeVries et al. 2001) was considerably
higher than the equivalent dose of THC (0.5 mg/kg) that
promoted extinction here. HU-210 is 100–1000 times
more potent than THC (Martin et al. 1999); therefore, the
dose of 0.02 mg/kg HU-210 would be the equivalent of
that between 2 mg/kg and 20 mg/kg THC. It is clear that
cannabinoids produce biphasic effects on systems such as
anxiety and locomotor activity at low and high doses
(Iversen 2000); therefore, lower doses of cannabinoids
may actually prevent reinstatement.
It has been suggested that the place-preference learn-
ing is a measure of “wanting” or “craving” (Robinson and
Berridge 1993). That is, cues previously paired with the
neurochemical consequences of a rewarding drug come to
elicit approach responses. It has been proposed that
“craving” resulting in drug-seeking behaviors may be
elicited by drug-associated cues (O’Brien et al. 1992;
Stewart and Wise 1992). Extinction of drug-associated
cues (“cue re-exposure”) is a method of extinguishing
craving and relapse (O’Brien et al. 1992). Strategies that
would accelerate extinction would potentially reduce the
likelihood of relapse. Our results suggest that low doses
of the cannabinoids, D
9
-THC and CBD, may facilitate
such extinction processes.
Acknowledgements The research in Canada was supported by the
Natural Sciences and Engineering Research Council of Canada and
the Canadian Institutes of Health Research; the Research in Jer-
usalem was supported by the Israel Science Foundation and the
National Institute on Drug Abuse (US).
References
Bardo MT, Neisewander JL, Miller JS (1986) Repeated testing
attenuates conditioned place preference with cocaine. Psycho-
pharmacology 89:239–243
Brodkin J, Moerschbaecher JM (1997) SR 141716A antagonizes
the disruptive effects of cannabinoid ligands on learning in rats.
J Pharm Exp Ther 282:1526–1532
Calcagnetti DJ, Schechter MD (1993) Extinction of cocaine-in-
duced place approach in rats: a validation of the “biases”
conditioning procedure. Brain Res Bull 30:696–700
Cheer JF, Kendall DA, Marsden CA (2000) Cannabinoid receptors
and reward in the rat: a conditioned place preference study.
Psychopharm 151:25–30
Cunningham CL (1998) Drug conditioning and drug-seeking be-
havior. In: O’Donohue W (ed) Learning and Behavior Therapy.
Allyn & Bacon, Boston, MA, pp 518–44
Cunningham CL, Henderson CM, Bormann NM (1998) Extinction
of ethanol-induced conditioned place preference and condi-
tioned place aversion: effects of naloxone. Psychopharmacol-
ogy 139:62–70
DeVries TJ, Shaham Y, Homberg JR, Crombag C, Schuurman K,
Diegen J, Vanderschuren LJMJ, Schoffelmeer ANM (2001) A
cannabinoid mechanism in relapse to cocaine seeking. Nature
Med 7:1151–1154
DeWit H, Stewart J (1981) Reinstatement of cocaine-reinforced
responding in the rat. Psychopharm 75:134–174
Hajos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive
receptor mediates inhibition of glutamatergic synaptic trans-
mission in the hippocampus. Neuroscience 106:1–4
Heyser CJ, Hampson RE, Deadwyler SA (1993) Effects of delta-9-
tetrahydrocannabinol on delayed match to sample performance
in rats: alterations in short-term memory associated with
changes in task specific firing of hippocampal cells. J Pharm
Exp Ther 264:294–307
Itzhak Y, Martin JL (2001) Cocaine-induced conditioned place
preference in mice: induction, extinction and reinstatement by
related psychostimulants. Neuropsychopharm 26:130–134
Iversen LL (2000) The Science of Marijuana. Oxford University
Press, NY
365
Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A
comparative analysis of the potential of cannabinoids and on-
dansetron to suppress cisplatin-induced emesis in the Suncus
murinus (house musk shrew). Psychopharmacology (in press)
Lichtman AH, Martin BR (1996) D-9-Tetrahydrocannabinol im-
pairs spatial memory through a cannabinoid receptor mecha-
nism. Psychopharmacology 126:125–131
Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol in-
terferes with the establishment and the expression of condi-
tioned rejection reactions produced by cyclophosphamide: a rat
model of nausea. Neuroreport 10:3769–3772
Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E,
Mechoulam R, Feldmann M (2000) The nonpsychoactive
cannabis constituent cannabidiol is an oral anti-arthritic thera-
peutic in murine collagen-induced arthritis. Proc Nat Acad Sci
U S A 97:9561–9566
Mallet PE, Beninger RJ (1998a) The cannabinoid CB1 receptor
antagonist SR 141716A attenuates the memory impairment
produced by D
9
-tetrahydrocannabinol or anandamide. Psycho-
pharmacology 140:11–19
Mallet PE, Beninger RJ (1998b) D(9)-tetrahydrocannabinol, but not
the endogenous cannabinoid receptor ligand, anandamide,
produces conditioned place avoidance. Life Sci 62:2431–2439
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio
MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W,
DiMarzo V, Lutz B (2002) The endogenous cannabinoid sys-
tem controls extinction of aversive memories. Nature 418:530–
534
Martin BR, Mechoulam R, Razdan RK (1999) Discovery and
characterization of endogenous cannabinoids. Life Sci 65:573–
95
Mechoulam R, Parker LA, Galilly R (2002) Cannabidiol: an
overview of some pharmacological aspects. J Clin Pharmacol
42:11S–19S
Meuller D, Perdikaris D, Stewart J (2000) Persistence and drug-
induced reinsttement of a morphine-induced conditioned place
preference. Behav Brain Res 136:389–397
Molina-Holgado F, Gonzalez MI, Leret ML (1995) Effects of D
9
-
tetrahydrocannabinol on short-term memory in the rat. Physiol
Behav 57:177–179
Nakamura EM, da Silva EA, Concilio GV, Wilkinson DA, Masur J
(1991) Reversible effects of acute and long-term administration
of D
9
-tetrahydrocannabinol (THC) on memory in the rat. Drug
Alcohol Depend 28:167–175
Nava F, Carta G, Battasi AM, Bessa GL (2000) D2 dopamine
receptors enable delta-9-tetrahydroicannabinol induced memo-
ry impairment and reduction of hippocampal extracellular
acetylcholine concentration. Br J Pharmacol 130:1201–1210
O’Brien CP, Childress AR, McLellan AT, Ehrman R (1992)
Classical conditioning in drug-dependent humans. Ann NY
Acad Sci 654:400–415
Parker LA, Gillies T (1995) THC-induced place and taste aversions
in Lewis and Sprague-Dawley rats. Behav Neurosci 109:71–78
Parker LA, McDonald RV (2000) Reinstatement of both a condi-
tioned place preference and a conditioned place aversion with
drug primes. Pharmacol Biochem Behav 66:559–61
Parker LA, Mechoulam R, Schievert C, Abbott LA (2002) Can-
nabidiol, a non-psychoactive component of cannabis and its
synthetic dimethylheptyl homolog suppress nausea in an ex-
perimental model with rats. NeuroReport 13:567–570
Parker LA, Mechoulam R, Fudge M, Schlievert C, Burton PD,
Abbott L (2003) Cannabinoid agonists interfere with and SR-
141716A potentiates lithium-induced conditioned rejection re-
actions: a rat measure of nausea. Psychopharmacology
166:156–162
Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Ef-
fects of cannabinoids on lithium-induced vomiting in the Sun-
cus murinus (house musk shrew). Psychopharmacology
171:156–161
Robinson TE, Berridge KC (1993) The neural basis of drug crav-
ing: an incentive-sensitization theory of addiction. Brain Res
Rev 18:247–291
Robinson L, Hinder L, Pertwee RG, Riedel G (2003) Effects of D
9
-
THC and WIN-55,212,2 on place preference in the water maze
in rats. Psychopharmacology 166:40–50
Schenk S, Partridge B (1999) Cocaine-seeking produced by ex-
perimenter-administered drug injections: dose-effect relation-
ships in rats. Psychopharmacology 147:285–290
Stewart J, Wise RA (1992) Reinstatement of heroin self-adminis-
tration habits: morphine prompts and naltrexone discourages
renewed responding after extinction. Psychopharmacology
108:79–84
Sutton MA, Schmidt EF, Choi KH, Schad CA, Whisler K, Sim-
mons D, Daranian DA, Moteggia LM, Neve RL, Self DW
(2003) Extinction-induced upregulation in AMPA receptors
reduces cocaine-seeking behaviour. Nature 421:70–75
Tzschentke TM, Schmidt WJ (1995) N-Methyl-d-aspartic-acid-re-
ceptor antagonists block morphine-induced conditioned place
preference in rats. Neurosci Lett 193:37–40
Varvel SA, Lichtman AH (2002) Evaluation of CB
1
receptor
knockout mice in the Morris water maze. J Pharm Exp Ther
301:915–924
Varvel SA, Hamm RJ, Martin BR, Lichtman AH (2001) Differ-
ential effects of D
9
-THC on spatial reference and working
memory in mice. Psychopharmacology 157:142–150
366
... According to the reports of human studies, CBD has sedative, anxiolytic, antidepressant, mood stabilizer, and anti-craving properties (16)(17)(18)(19). Lately, due to the anti-inflammatory and antioxidative (20) neuroprotective (21) properties of CBD and its hindrance to the rewarding effects of morphine (8), researchers have paid attention to it. ...
... Recent evidence demonstrated that high doses of CBD (10 and 20 mg/kg) significantly increased Intracranial Self-Stimulation (ICSS) threshold frequency in the medial forebrain bundle (9). This possibly will denote the anti-reward effect of CBD; nevertheless, in the mentioned study, a 5 mg/kg dosage CBD, although efficient to reduce the morphine effects, did not adjust the acute strengthening properties of cocaine (8); it is also consistent with a previous report suggesting that CBD does not induce conditioned place preference (CPP) and therefore lacks hedonic properties (18). Several animal works have studied that single or repeated CBD administration can decrease the rewarding effects of cocaine and METH. ...
... CBD inhibits the dopamine uptake, but this effect's pharmacological relevance in a human being is unidentified (27,28). CBD was not inherently hedonistic (18). Recently the 80 mg/kg CBD effects on reducing the motivation to self-administer METH and diminished methamphetamine-primed relapse to methamphetamine-seeking behavior following extinction were investigated in an animal study (14). ...
Article
Full-text available
As a strong and addictive psychostimulant, methamphetamine (METH) is often misused worldwide. Although relapse is the greatest challenge to the effective treatment of drug dependency, now, for METH addiction, there is not available accepted pharmacotherapy. To characterize a probable new target in this indication, a biological system comprised of endocannabinoids, known as the endocannabinoid system (ECS), has been advised. As a non-psychotomimetic Phytocannabinoid in Cannabis sativa, cannabidiol (CBD) has been used in preclinical and clinical studies for treating neuropsychiatric disorders. In this review article, we focus on the effects of CBD in the treatment of addiction in a preclinical investigation concerning the pharmaceutic effectiveness and the underlying mechanisms of action on drug abuse specially METH. Growing evidence shows that CBD is a potential therapeutic agent in reducing drug reward, as evaluated in conditioned place preference (CPP), brain-stimulation reward paradigms, and self- administration. Furthermore, CBD plays an effective role in decreasing relapse in animal research. Through multiple-mechanisms, there is a belief that CBD modulates brain dopamine responding to METH, resulting in a reduction of METH-seeking behaviors. As our studies indicate, CBD can decrease METH addiction-associated problems, for example, symptoms of withdrawal and craving. It is needed for conducting more preclinical investigations and upcoming clinical trials to entirely assess the CBD capability as interference for METH addiction.
... Since CBD carries mild side effects in animal preclinical and human studies (Iffland and Grotenhermen, 2017;Taylor et al., 2018), and exhibits no rewarding properties (Babalonis et al., 2017;Parker et al., 2004), it may be introduced as a great therapeutic candidate for drug abuse. Recently, it has been established that CBD is effective for the inhibition of reinforcing and rewarding properties of drugs (Calpe-López et al., 2019;Chye et al., 2019;Elsaid et al., 2019;Mandolini et al., 2018;Rodrigues et al., 2020) such as opioids Prud'homme et al., 2015), psychostimulants (Calpe-López et al., 2021;Rodrigues et al., 2020), alcohol (Nona et al., 2019;Turna et al., 2019), and cannabis (Freeman et al., 2019(Freeman et al., , 2020 in both humans and animals. ...
... From its first identification, in 1940 (Adams et al., 1940), CBD has been extensively studied and found to exert many potentially therapeutic pharmacological effects, displaying antipsychotic, antinociceptive, anticonvulsant, anxiolytic, anti-inflammatory, anti-oxidant, and neuroprotective properties (Bergamaschi et al., 2011;Calpe-López et al., 2019;Karimi-Haghighi et al., 2020;Razavi et al., 2020). Until now, CBD has been shown to exhibit minor adverse effects or toxicity and therefore demonstrates an acceptable safety profile in preclinical non-human and human studies (Iffland and Grotenhermen, 2017;Taylor et al., 2018), while exhibiting no rewarding effect (Babalonis et al., 2017;Parker et al., 2004). Based on these data, the use of CBD has recently been considered as a potential treatment for substance use disorders such as addiction. ...
... Unlike THC, CBD is a negative allosteric modulator of cannabinoid type 1 (CB1R) and 2 (CB2R) receptors (Laprairie et al., 2015;Martínez-Pinilla et al., 2017) (Fig. 1). The role of CB1R in substance abuse disorders is controversial and may depend upon the phase of drug abuse (Galaj et al., 2020;Parker et al., 2004). Amongst CB1R inverse agonists or antagonists, application of AM251 or SR141716 has failed to reverse the ameliorative effects of CBD on cocaine-related reward (Galaj et al., 2020;Gerdeman et al., 2008), while the neutral antagonist AM4113 has been found to inhibit the suppressive impact of CBD on cue-induced reinstatement of cocaine-seeking (Luján et al., 2020). ...
Article
Background Cannabidiol (CBD) is one of the major constituents of Cannabis sativa L. that lacks psychotomimetic and rewarding properties and inhibits the rewarding and reinforcing effects of addictive drugs such as cocaine, methamphetamine (METH), and morphine. Additionally, CBD's safety profile and therapeutic potential are currently evaluated in several medical conditions, including pain, depression, movement disorders, epilepsy, multiple sclerosis, Alzheimer's disease, ischemia, and substance use disorder. There is no effective treatment for substance use disorders such as addiction, and this review aims to describe preclinical and clinical investigations into the effects of CBD in various models of opioid, psychostimulant, cannabis, alcohol, and nicotine abuse. Furthermore, the possible mechanisms underlying the therapeutic potential of CBD on drug abuse disorders are reviewed. Methods The current review considers and summarizes the preclinical and clinical investigations into CBD's effects in various models of drug abuse include opioids, psychostimulants, cannabis, alcohol, and nicotine. Results Several preclinical and clinical studies have proposed that CBD may be a reliable agent to inhibit the reinforcing and rewarding impact of drugs. Conclusions While the currently available evidence converges to suggest that CBD could effectively reduce the rewarding and reinforcing effects of addictive drugs, more preclinical and clinical studies are needed before CBD can be added to the therapeutic arsenal for treating addiction.
... With promising findings of CBD for addiction of other substances, research interest has increased in examining its effect on psychostimulant addiction. Preclinical studies have been performed by injecting CBD (5 mg/kg i.p.) into rats after cocaine-and amphetamine-induced conditioned place preference [108]. An extinction trial was then given and found that CBD-treated mice spent less time on the psychostimulants-paired floor as compared with vehicle-treated mice, meaning that CBD potentiated the extinction of place preference learning induced by both psychostimulants [108]. ...
... Preclinical studies have been performed by injecting CBD (5 mg/kg i.p.) into rats after cocaine-and amphetamine-induced conditioned place preference [108]. An extinction trial was then given and found that CBD-treated mice spent less time on the psychostimulants-paired floor as compared with vehicle-treated mice, meaning that CBD potentiated the extinction of place preference learning induced by both psychostimulants [108]. CBD was also found to be protective against seizures and acute liver injury associated with cocaine intake in mice [109]. ...
Article
Full-text available
The use of cannabidiol (CBD) for treating brain disorders has gained increasing interest. While the mechanism of action of CBD in these conditions is still under investigation, CBD has been shown to affect numerous different drug targets in the brain that are involved in brain disorders. Here we review the preclinical and clinical evidence on the potential therapeutic use of CBD in treating various brain disorders. Moreover, we also examine various drug delivery approaches that have been applied to CBD. Due to the slow absorption and low bioavailability with the current oral CBD therapy, more efficient routes of administration to bypass hepatic metabolism, particularly pulmonary delivery, should be considered. Comparison of pharmacokinetic studies of different delivery routes highlight the advantages of intranasal and inhalation drug delivery over other routes of administration (oral, injection, sublingual, buccal, and transdermal) for treating brain disorders. These two routes of delivery, being non-invasive and able to achieve fast absorption and increase bioavailability, are attracting increasing interest for CBD applications, with more research and development expected in the near future.
... Some of the major differences between THC and CBD are their highly divergent central effects. Indeed, through different preclinical experimental approaches (i.e., conditioned place preference and electrical brain stimulation), it has been demonstrated that CBD, unlike THC, does not show any rewarding effects [87][88][89] or psychoactive properties [90][91][92]; this may be due, in part, to its inability to alter extracellular dopamine (DA) levels in the ventral striatum [83]. Moreover, whereas THC exposure is able to induce dysregulation of mesolimbic DA transmission and affect salience stimuli evaluation [93][94][95][96], CBD is able to normalize/restore aberrant DA signaling and salience processing [93][94][95][96]. ...
Article
Full-text available
Cannabis is the most used drug of abuse worldwide. It is well established that the most abundant phytocannabinoids in this plant are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These two compounds have remarkably similar chemical structures yet vastly different effects in the brain. By binding to the same receptors, THC is psychoactive, while CBD has anxiolytic and antipsychotic properties. Lately, a variety of hemp-based products, including CBD and THC, have become widely available in the food and health industry, and medical and recreational use of cannabis has been legalized in many states/countries. As a result, people, including youths, are consuming CBD because it is considered “safe”. An extensive literature exists evaluating the harmful effects of THC in both adults and adolescents, but little is known about the long-term effects of CBD exposure, especially in adolescence. The aim of this review is to collect preclinical and clinical evidence about the effects of cannabidiol.
... Whereas a brief but sufficient retrieval session maintains the memory trace through reconsolidation, a prolonged/repeated session inhibits it because of extinction learning ( Duvarci and Nader, 2004 ;Suzuki et al., 2004 ;Bouton et al., 2006 ;Lee et al., 2006 ;Bustos et al., 2009 ;Mamiya et al., 2009 ;de la Fuente et al., 2011 ;Franzen et al., 2019 ). Overall, systemic CBD treatment has been reported to potentiate the extinction ( Parker et al., 2004 ;Bitencourt et al., 2008 ;Das et al., 2013 ;Do Monte et al., 2013 ;Song et al., 2016 ;Kashefi et al., 2021 ; see also Kwee et al., 2022 ) and disrupt the reconsolidation ( Stern et al., 2012 ;Gazarini et al., 2014Gazarini et al., , 2015de Carvalho and Takahashi, 2017 ;Murkar et al., 2019 ;Bayer et al., 2022 ;Bolsoni et al., 2022 ;Han et al., 2022 ), thereby attenuating the memory's behavioral manifestation. Such reduction, however, is presumed to be more permanent following reconsolidation disruption ( Stern et al., 2012 ;Raymundi et al., 2020a ), as the extinguished response can spontaneously recover, renew, or reinstate (for a review, see Bouton et al., 2021 ). ...
Article
Women present increased susceptibility to anxiety- and stress-related disorders compared to men. A potentially promising pharmacological-based strategy to regulate abnormal aversive memories disrupts their reconsolidation stage after reactivation and destabilization. Male rodent findings indicate that cannabidiol (CBD), a relatively safe and effective treatment for several mental health conditions, can impair the reconsolidation of aversive memories. However, whether and how CBD influences it in females is still unknown. The present study addressed this question in contextually fear-conditioned female rats. We report that systemically administered CBD impaired their reconsolidation, reducing freezing expression for over a week. This action was restricted to a time when the reconsolidation presumably lasted (< six hours post-retrieval) and depended on memory reactivation/destabilization. Moreover, the impairing effects of CBD on memory reconsolidation relied on the activation of cannabinoid type-1 but not type-2 receptors located in the CA1 subregion of the dorsal hippocampus. CBD applied directly to this brain area was sufficient to reproduce the effects of systemic CBD treatment. Contextual fear memories attenuated by CBD did not show reinstatement, an extinction-related feature. By demonstrating that destabilized fear memories are sensitive to CBD and how it hinders mechanisms in the DH CA1 that may restabilize them in female rats, the present findings concur that reconsolidation blockers are viable and could be effective in disrupting abnormally persistent and distressing aversive memories such as those related to posttraumatic stress disorder.
Article
Introduction: Methamphetamine (METH) is an addictive psychostimulant that facilitates dopamine transmission to the nucleus accumbens (NAc), resulting in alterations in the mesocorticolimbic brain regions. Cannabidiol (CBD) is considered the second most abundant component of cannabis and is believed to decrease the METH effects. Reversing psychostimulant-induced abnormalities in the mesolimbic dopamine system is the main mechanism for this effect. Various other mechanisms have been proposed: increasing endocannabinoid system activity and modulating gamma-aminobutyric acid (GABA) and glutamate neurons in NAc. However, the exact CBD action mechanisms in reducing drug addiction and relapse vulnerability remain unclear. Methods and Results: The present study aimed to investigate the effects of intracerebroventricular (ICV) administrating 5, 10, and 50 μg/5 μL CBD solutions on the extinction period and reinstatement phase of a METH-induced conditioned place preference. This research also aimed to examine the NAc D1-like dopamine receptor (D1R) and D2-like dopamine receptor (D2R) roles in the effects of CBD on these phases, as mentioned earlier, using SCH23390 and sulpiride microinjections as an antagonist of D1R and D2R. The obtained results showed that microinjection of CBD (10 and 50 μg/5 μL, ICV) suppressed the METH-induced reinstatement and significantly decreased mean extinction latency in treated groups compared to both vehicles and/or untreated control groups. In addition, the results demonstrated that administrating intra-accumbal SCH23390 (1 and 4 μg/0.5 μL saline) reversed the inhibitory effects of CBD on extinction and reinstatement phases while different doses of sulpiride (0.25, 1, and 4 μg/0.5 μL; dimethyl sulfoxide 12%) could not alter the CBD effects. Conclusions: In summary, this study showed that CBD made shorter extinction latencies and suppressed the METH reinstatement, in part, by interacting with D1R but not D2R in the NAc.
Article
Preclinical research suggests that enhancing CB1 receptor agonism may improve fear extinction. In order to translate this knowledge into a clinical application we examined whether cannabidiol (CBD), a hydrolysis inhibitor of the endogenous CB1 receptor agonist anandamide (AEA), would enhance the effects of exposure therapy in treatment refractory patients with anxiety disorders. Patients with panic disorder with agoraphobia or social anxiety disorder were recruited for a double-blind parallel randomised controlled trial at three mental health care centres in the Netherlands. Eight therapist-assisted exposure in vivo sessions (weekly, outpatient) were augmented with 300 mg oral CBD (n = 39) or placebo (n = 41). The Fear Questionnaire (FQ) was assessed at baseline, mid- and post-treatment, and at 3 and 6 months follow-up. Primary analyses were on an intent-to-treat basis. No differences were found in treatment outcome over time between CBD and placebo on FQ scores, neither across (β = 0.32, 95% CI [-0.60; 1.25]) nor within diagnosis groups (β = -0.11, 95% CI [-1.62; 1.40]). In contrast to our hypotheses, CBD augmentation did not enhance early treatment response, within-session fear extinction or extinction learning. Incidence of adverse effects was equal in the CBD (n = 4, 10.3%) and placebo condition (n = 6, 15.4%). In this first clinical trial examining CBD as an adjunctive therapy in anxiety disorders, CBD did not improve treatment outcome. Future clinical trials may investigate different dosage regimens.
Article
Full-text available
Drug use is highly concordant among members of adolescent and young adult peer groups. One potential explanation for this observation is that drugs may increase the reinforcing effects of social contact, leading to greater motivation to establish and maintain contact with other members of the peer group. Several classes of drugs, particularly drugs that increase synaptic dopamine, increase the reinforcing effects of contextual stimuli, but the extent to which these drugs enhance the reinforcing effects of social contact is not known. The purpose of this study was to determine the extent to which drugs that increase synaptic dopamine, norepinephrine, and serotonin enhance the positive reinforcing effects of social contact. To this end, male and female Long-Evans rats were pretreated with acute doses of the selective dopamine reuptake inhibitor, WIN-35,428, the selective norepinephrine reuptake inhibitor, atomoxetine, the selective serotonin reuptake inhibitor, fluoxetine, the non-selective monoamine reuptake inhibitor, cocaine, and the non-selective monoamine releasers d -amphetamine and (±)-MDMA. Ten minutes later, the positive reinforcing effects of 30-s access to a same-sex social partner was examined on a progressive ratio schedule of reinforcement. To determine whether the reinforcement-altering effects of these drugs were specific to the social stimulus, the reinforcing effects of a non-social stimulus (30-s access to an athletic sock of similar size and coloring as another rat) was determined in control subjects. WIN-35,428, d -amphetamine, and cocaine, but not atomoxetine, fluoxetine, or MDMA, dose-dependently increased breakpoints maintained by a social partner under conditions in which responding maintained by a non-social stimulus was not affected. These data indicate that increases in extracellular dopamine, but not extracellular norepinephrine or serotonin, increases the positive reinforcing effects of social contact in both male and female rats. These data also provide support for the hypothesis that some drugs with high abuse liability increase the motivation to establish and maintain contact with social peers.
Article
Background and Purpose: This study sought to determine whether cannabidiol (CBD) or a CBD derivative, CBD monovalinate monohemisuccinate (CBD-val-HS), could attenuate the development of oxycodone reward while retaining its analgesic effects. Experimental Approach: To determine the effect on oxycodone reward, animals were enrolled in the conditioned place preference paradigm and received either saline or oxycodone (3.0 mg/kg) in combination with either CBD or CBD-val-HS utilizing three sets of drug-/no drug-conditioning trials. To determine if the doses of CBD or CBD-val-HS that blocked opioid reward would affect nociceptive processes, animals were enrolled in the hot plate and abdominal writhing assays when administered alone or in combination with a subanalgesic (1.0 mg/kg) or analgesic (3.0 mg/kg) dose of oxycodone. Key Results: Results from condition place preference demonstrated CBD was not able attenuate oxycodone place preference while CBD-val-HS attenuated these rewarding effects at 8.0 mg/kg and was void of rewarding or aversive properties. In contrast to CBD, CBD-val-HS alone produced analgesic effects in both nociceptive assays but was most effective compared with oxycodone against thermal nociception. Of interest, there was a differential interaction of CBD and CBD-val-HS×oxycodone across the two nociceptive assays producing subadditive responses on the hot plate assay, whereas additive responses were observed in the abdominal writhing assay. Conclusion: These findings suggest CBD-val-HS alone, a nonrewarding analgesic compound, could be useful in pain management and addiction treatment settings.
Article
Full-text available
The effects of morphine, naltrexone, and nalorphine were studied in rats trained to lever-press for intravenous heroin and then tested under conditions of non-reinforcement. Animals were reinforced for lever-pressing on a continuous reinforcement schedule (100 micrograms/kg per infusion) for 2-3 h each day following which reinforcement was terminated and animals were studied under extinction conditions for the remainder of the session. Each day following the termination of responding under extinction conditions, animals were given a single injection of saline, morphine, nalorphine, or naltrexone; lever-pressing under the extinction conditions was then observed for several hours. When animals adapted to this regimen, very low levels of responding were seen following saline injections; morphine (2 or 10 mg/kg) reinstated vigorous responding that lasted 1-4 h. Naltrexone (2 mg/kg) suppressed responding below the levels seen after saline, and nalorphine (10 mg/kg) had the same effect as saline. These observations support the view that opioid-seeking behavior is primed by the proponent or opioid-like actions of opioids and not by the opponent or drug-opposite effects associated with opioid withdrawal.
Article
This paper presents a biopsychological theory of drug addiction, the 'Incentive-Sensitization Theory'. The theory addresses three fundamental questions. The first is: why do addicts crave drugs? That is, what is the psychological and neurobiological basis of drug craving? The second is: why does drug craving persist even after long periods of abstinence? The third is whether 'wanting' drugs (drug craving) is attributable to 'liking' drugs (to the subjective pleasurable effects of drugs)? The theory posits the following. (1) Addictive drugs share the ability to enhance mesotelencephalic dopamine neurotransmission. (2) One psychological function of this neural system is to attribute 'incentive salience' to the perception and mental representation of events associated with activation of the system. Incentive salience is a psychological process that transforms the perception of stimuli, imbuing them with salience, making them attractive, 'wanted', incentive stimuli. (3) In some individuals the repeated use of addictive drugs produces incremental neuroadaptations in this neural system, rendering it increasingly and perhaps permanently, hypersensitive ('sensitized') to drugs and drug-associated stimuli. The sensitization of dopamine systems is gated by associative learning, which causes excessive incentive salience to be attributed to the act of drug taking and to stimuli associated with drug taking. It is specifically the sensitization of incentive salience, therefore, that transforms ordinary 'wanting' into excessive drug craving. (4) It is further proposed that sensitization of the neural systems responsible for incentive salience ('for wanting') can occur independently of changes in neural systems that mediate the subjective pleasurable effects of drugs (drug 'liking') and of neural systems that mediate withdrawal. Thus, sensitization of incentive salience can produce addictive behavior (compulsive drug seeking and drug taking) even if the expectation of drug pleasure or the aversive properties of withdrawal are diminished and even in the face of strong disincentives, including the loss of reputation, job, home and family. We review evidence for this view of addiction and discuss its implications for understanding the psychology and neurobiology of addiction.
Article
This paper presents a biopsychological theory of drug addiction, the ‘Incentive-Sensitization Theory’. The theory addresses three fundamental questions. The first is: why do addicts crave drugs? That is, what is the psychological and neurobiological basis of drug craving? The second is: why does drug craving persist even after long periods of abstinence? The third is whether ‘wanting’ drugs (drug craving) is attributable to ‘liking’ drugs (to the subjective pleasurable effects of drugs)? The theory posits the following.
Article
Repetitive use of psychoactive drugs produces a variety of learned behaviors. These can be classified in the laboratory according to an operant/classical paradigm, but in vivo the two types of learning overlap. The classically conditioned responses produced by drugs are complex and bi-directional. There has been progress in classifying and predicting the types of conditioned responses, but little is known of mechanisms. New techniques for understanding brain function such as micro-dialysis probes in animals and advanced imaging techniques (PET and SPECT) in human subjects may be utilized in conditioning paradigms to "open the black box." Because the existence of conditioned responses in drug users is now well established, clinical studies have been instituted to determine whether modification of conditioned responses can influence clinical outcome. A recently completed study in cocaine addicts has produced evidence that outcome can be improved by a passive extinction technique over an 8-week outpatient treatment program.
Article
A study was designed to develop a measure of both acute and chronic effects of THC administration on memory in the rat. Errors in an 8-arm radial maze, before and after two delay intervals (5 s and 1 h, introduced between the fourth and the fifth arm choice), constituted the principal dependent measures. The first experiment involved testing the animals shortly after administration of 1.25 mg/kg THC. The drug did not affect performance in the pre-delay tests, although a significant effect was observed after the 5-s delay but not after 1-h delay. In the second experiment, 5 mg/kg THC or saline were administered 6 days/week for 90 days. Testing was conducted 18 h after each drug administration. During chronic administration the pre-delay performance did not differ between groups but the post-delay performance of the THC group deteriorated in a gradual manner, relative to their controls, in both the 5-s and 1-h delay conditions. After discontinuation of drug administration, the differences between groups reversed only after 30 days. The results provided evidence that both acute and chronic administration of THC affected working-memory in the radial arm maze test, although it did not interfere with the general cues of the task (reference memory). Chronic drug effects on memory were reversible after prolonged abstinence. Thus, the 8-arm radial maze task proved to be a useful measure of THC effects on memory and could be further used to investigate more thoroughly the mechanisms involved in such drug effects.(ABSTRACT TRUNCATED AT 250 WORDS)
Article
Cocaine-treated rats acquired a preference for cocaine-associated contextual stimuli (CS) relative to saline-injected control rats. However, when animals were given repeated tests for conditioned place preference intermittent between conditioning trials, they displayed an attenuation in strength of conditioning. This attenuation was not due to pharmacologic tolerance (Experiment 1), but rather reflected a disruption in learning due to exposure to the CS alone (Experiment 2). Like other examples of classical conditioning, the strength of the conditioned response (CR) as assessed by the conditioned place preference model may be influenced by partial reinforcement.
Article
Non-contingent, 'priming' IV drug injections led to reinstatement of heroin-reinforced responding after a period of extinction. Rats implanted with IV catheters were trained to self-administer heroin (100 micrograms/kg/infusion diacetylmorphine HCl) and were given test sessions consisting of a period of self-administration followed by extinction conditions. 'Priming' infusions of heroin and other drugs were presented during extinction and lever pressing following the injection was observed. Priming injections of 50, 100 and 200 micrograms/kg heroin effectively restored responding after a period of extinction. Morphine and, to a lesser extent, amphetamine and apomorphine also reinstated heroin-reinforced responding whereas cocaine and clonidine did not. These results may help our understanding of 'relapse of drug-taking' behavior.
Article
Non-contingent "priming" drug injections and conditioned stimuli associated with drug injections led to reinstatement of responding after a period of extinction. Rats implanted with intravenous catheters were trained to self-administer cocaine 1 mg/kg/injection), and then given daily test sessions consisting of a period of self-administration followed by extinction conditions. Test drug injections or conditioned stimuli were presented during extinction and the latency to the first response and the total number of responses following the treatment were measured. Cocaine injections of 0.5, 1.0, and 2.0 mg/kg restored responding during extinction, regardless of the duration of the extinction period (between 10 min and 180 min) since drug self-administration. Amphetamine, apomorphine, and morphine but not ethanol, heroin, or methohexital reinstated previously cocaine-reinforced responding. Amphetamine, cocaine, and morphine did not increase responding in animals trained to bar press only for food reinforcement, suggesting that the reinstatement effect is specific to drug-reinforced responses. The statement effect is specific to drug-reinforced responses. The final experiment showed that a tone that had been paired with drug infusions acquired a statistically significant tendency to facilitate responding when tested during extinction but this effect disappeared after the first test presentation of the tone.
Article
We addressed the question of whether (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) and DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP37849), a non-competitive and a competitive N-methyl-D-aspartate (NMDA) receptor antagonist, respectively, are able to block morphine-induced conditioned place preference (CPP). MK-801 alone (0.1 mg/kg) produced neither a place preference nor a place aversion, but was able to completely block morphine-induced CPP. CGP37849 alone (10 mg/kg) produced a small but significant CPP, and was able to significantly attenuate morphine-induced CPP. These results cannot be due to simple additive effects of drug actions, but suggest that NMDA receptors play a complex role in the development of morphine CPP.